drugset / Trial / NCT06363825
A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of TAE+HAIC combined with camrelizumab and apatinib in the treatment of advanced liver cancer with high tumor load
Timeline
- Start
- 2024-04-12
- Primary completion
- 2026-04-11
- Completion
- 2027-05-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Rivoceranib | Small molecule | 250 mg | Oral |
| Background | LV | Unknown | 400 mg/m2 | Other |
| Background | Oxaliplatin | Small molecule | 85 mg/m2 | Other |
| Background | fluorouracil | Small molecule | 400 mg/m2 | Other |
| Background | fluorouracil | Small molecule | 2400 mg/m2 | Other |